Atrial enlargement ivcd4/2/2023 ![]() Among subgroups, patients without a history of prior arrhythmia exhibited a pronounced increase in the risk for the development of arrhythmogenic cardiotoxicity (3.2‐fold P<0.001).Ĭlose cardiac monitoring and symptom awareness should be considered in patients with lymphoproliferative disorders undergoing lymphoma treatments even without traditional risk factors for arrhythmia. Multivariate analysis showed that BTKi treatment was associated with a 4.3‐fold ( P<0.001) increased risk for arrhythmic event ( P<0.001) compared with no treatment, whereas non‐BTKi treatment was associated with a 2‐fold ( P<0.001) risk increase. Atrial fibrillation/flutter was the most common type of arrhythmia accounting for 41%. The overall rate of any arrhythmia at 5 years following the initiation of BTKi was (61%) compared with (18%) without treatment. Median age was 64 (54–72) years, and 42% were women. Multivariate Cox regression analysis was used to assess the risk of arrhythmic events with treatments categorized as Bruton tyrosine kinase inhibitor (BTKi), mainly ibrutinib/non‐BTKi treatment versus no treatment. ![]() Cardiac arrhythmias-atrial fibrillation/flutter, supraventricular tachycardia, ventricular arrhythmia, and bradyarrhythmia-were identified using International Classification of Diseases, Tenth Revision ( ICD‐10) codes. The study population comprised 2064 patients included in the University of Rochester Medical Center Lymphoma Database from January 2013 to August 2019. Stroke: Vascular and Interventional Neurology.Journal of the American Heart Association (JAHA).Circ: Cardiovascular Quality & Outcomes.Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB).
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |